Muller J E
J Am Coll Cardiol. 1983 Mar;1(3):893-6. doi: 10.1016/s0735-1097(83)80205-8.
There is intense scientific interest in the possibility that the acute administration of a fibrinolytic agent might be of benefit to patients with acute myocardial infarction. This hypothesis, which will soon be tested in a major trial by the National Heart, Lung, and Blood Institute, has emerged from a confluence of advances in three areas: increased knowledge about the role of thrombosis in myocardial infarction, the development of fibrinolytic agents and the recognition that ischemic myocardial tissue might be salvaged from necrosis by timely reperfusion. Examination of the manner in which these areas of knowledge developed and interacted not only illuminates our path to this specific therapeutic possibility, but also demonstrates the indirect and stuttering manner in which important new ideas often evolve.
对于急性心肌梗死患者而言，急性给予纤溶药物可能有益，这一可能性引发了科学界的浓厚兴趣。这一假说即将由美国国立心肺血液研究所进行一项大型试验验证，它源于三个领域进展的融合：对血栓形成在心肌梗死中作用的认识增加、纤溶药物的研发以及认识到通过及时再灌注可使缺血心肌组织免于坏死。审视这些知识领域的发展及相互作用方式，不仅能阐明我们通向这一特定治疗可能性的道路，还能展示重要新观念常常以间接且起伏不定的方式演变。
